Medicines Formulary

Medicines A–Z

B

Drug name	NICE TAs	Comments
Botulism antitoxin
Brentuximab injection	TA446 - Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma TA478 - Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma TA577 - Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma TA641 - Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma	National CDF list. For hospital use only.
Brevinor		Umbrella service only
Brexucabtagene autoleucel	TA893 - Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
Brigatinib (Alunbrig®)	TA571 - Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib TA670 - Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
Brimonidine 3mg/g (Mirvaso®)
Brinzolamide 1% and Brimonidine 0.2% eye drops (Simbrinza)		Specialist ophthalmologist recommendation
Brinzolamide eye drops		Specialist ophthalmologist recommendation
Brivaracetam (Briviact ®) injection
Brivaracetam (Briviact®)		Initiation by Tertiary Epilepsy Specialist only. For adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age, with severe refractory epilepsy warranting tertiary specialist input for patients who have tried three or more AEDs. The patient has used levetiracetam and has documentation of intolerance and patient is using a third line agent (perampanel, zonisamide, lacosamide, eslicarbazepine) which would be replaced by brivaracetam. ESCA required.

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.